Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880074 · ClinicalTrials.gov registry record · Phase 1
FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00880074: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00880074 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00880074, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors and measure a patient's response to treatment.
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- DRUG Fluorothymidine F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-04-09 |
| Est. Completion | 2022-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00880074
The ClinicalTrials.gov registry entry for NCT00880074 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Positron Emission Tomography is the first listed.
NCT00880074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00880074 about?
NCT00880074 is a clinical study titled "FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies". This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors an...
What is the current status of trial NCT00880074?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-04-09. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT00880074?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Fluorothymidine F-18 (DRUG).
Who is sponsoring clinical trial NCT00880074?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.